At first glance, it is surprising since increased ROS production and oxidative stress are generally associated with arteriosclerosis and cardiovascular disease [28], and pharmacological inhibition of CYBB is associated with a delayed atherosclerotic progression in animal models [29]. Here, CYBB is linked to cardiovascular disorder.